ML20070Q265
| ML20070Q265 | |
| Person / Time | |
|---|---|
| Site: | Beaver Valley |
| Issue date: | 03/22/1991 |
| From: | Sieber J DUQUESNE LIGHT CO. |
| To: | NRC OFFICE OF INFORMATION RESOURCES MANAGEMENT (IRM) |
| References | |
| NUDOCS 9103280296 | |
| Download: ML20070Q265 (2) | |
Text
9 EK]UOSTE @ Dily yff,i""'""".cm""n"".
w.m,w,m a u March 22, 1991 n n o se
%aw WwI ks ea< Cen in ? ht b ia%
U.
S.
Nuclear Regulatory Commission Attn:
Document Control Desk Washington, DC 20555
Subject:
Deaver Valley Power Station, Unit No. I and No. 2 BV-1 Docket No. 50-334, License No. DPR-66 DV-2 Docket No. 50-412, License No. NPF-73 Fitness-For-Duty Program Six Month Report Supplement By letter dated March 13, 1991, we provided the Fitness-For-Duty Program Six Month Report for the period July 1, 1990 through December 31, 1990.
The attached supplement to the above report provides a summary of management actions as required by 10 CFR 26.71 (d).
If there are any questions concerning this report, please contact Ms. Pat Casasanta at (412) 393-5238.
Sincerely, J.
D.
Sieber Vice President Nuclear Group Attachment cc:
Mr.
J.
Beall, Sr. Resident Inspector Mr. T.
T.
Martin, NRC Region I Administrator Mr.
A.
W.
DeAgazio, Project Manager I
I 9103280296 910322 PDR ADOCK 05000334 R
Q}3 PDR
_~..--. _ - - -.- -
SUMMARY
OF MANAGEMENT' ACTIONS 1.
Problem Identified:
Deginning 10/90, Duquesne Light Company identified discrepancies with results reported on fourteen blind proficiency samples sont to-Roche Biomedical.
Investigation proved the following:
a.
The blind samples supplied to the licensco were felt to be unstable.
I i
b.
Roche Laboratory's method of screening appeared to have failed.
this was cased on Roche obtaining GC/MS values greater than 1000 on repeat analysis.
c.
It
- appeared, on one THC cample, that the antiserum used was too specific.
The licensee's audit of Roche Biomedical indicated a
low-bias on the analysis for THC carlier in 1990.
To arrive at the above conclusions, the licenace used the services of another DHHS certified laboratory and purchased Bio-Rad, FDA
- approved, blind samples.
Using the split
- method, samples were sent to Roche Biomedical and another DHHS certified lab.
Results and screening mathods were compared and conclusions drawn to explain the falso negative reports.
-Solution Implemented:
To-correct these problems, the licensee'has initiated the services of Clinical. Pathology Facility, Pittsburgh,-PA, as its primary lab, and now purchase FDA approved bl'ind proficiency samples for quality
- control, t
o
- _ _ _,